What is ORIC Pharmaceuticals Profitability Rank?
ORIC Pharmaceuticals has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
ORIC Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, ORIC Pharmaceuticals's Piotroski F-Score is 3.
Competitive Comparison of ORIC Pharmaceuticals's Profitability Rank
For the Biotechnology subindustry, ORIC Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ORIC Pharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's Profitability Rank distribution charts can be found below:
* The bar in red indicates where ORIC Pharmaceuticals's Profitability Rank falls into.
ORIC Pharmaceuticals Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
ORIC Pharmaceuticals has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
ORIC Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
ORIC Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
ORIC Pharmaceuticals (ORIC Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
Executives
| Jacob Chacko |
director, officer: President and CEO |
C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121 |
| Pratik S Multani |
officer: Chief Business Officer |
C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
| Dominic Piscitelli |
officer: Chief Financial Officer |
C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121 |
| Pfizer Inc |
10 percent owner |
66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
| Column Group Llc |
10 percent owner |
1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
| Column Group Ii Gp, Lp |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Peter Svennilson |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Column Group Ii, Lp |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| David V Goeddel |
10 percent owner |
C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Angie You |
director |
C/O AMUNIX PHARMACEUTICALS, INC., 2 TOWER PLACE, #1100, SOUTH SAN FRANCISCO CA 94080 |
| Richard A. Heyman |
director |
5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121 |
| Steven L. Hoerter |
director |
C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
| Richard H Scheller |
director |
C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990 |
| Orbimed Advisors Llc |
director |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Carl L Gordon |
director |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ORIC has been successfully added to your